Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia

Background & Aims The World Health Organisation (WHO) Prevention & Control of Viral Hepatitis Infection: Framework for Global Action offers a global vision for the prevention and control of viral hepatitis. In October 2012, the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hepatology 2013-11, Vol.59 (5), p.1073-1080
Hauptverfasser: Chen, Ding-Shinn, Locarnini, Stephen, Wait, Suzanne, Bae, Si-Hyun, Chen, Pei-Jer, Fung, James Y.Y, Kim, Hong Soo, Lu, Sheng-Nan, Sung, Joseph, Tanaka, Junko, Wakita, Takaji, Ward, John, Wallace, Jack
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1080
container_issue 5
container_start_page 1073
container_title Journal of hepatology
container_volume 59
creator Chen, Ding-Shinn
Locarnini, Stephen
Wait, Suzanne
Bae, Si-Hyun
Chen, Pei-Jer
Fung, James Y.Y
Kim, Hong Soo
Lu, Sheng-Nan
Sung, Joseph
Tanaka, Junko
Wakita, Takaji
Ward, John
Wallace, Jack
description Background & Aims The World Health Organisation (WHO) Prevention & Control of Viral Hepatitis Infection: Framework for Global Action offers a global vision for the prevention and control of viral hepatitis. In October 2012, the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) organised the North Asia Workshop on Viral Hepatitis in Taipei to discuss how to implement the WHO Framework in the North Asia region. This paper presents outcomes from this workshop. Methods Twenty-eight representatives from local liver associations, patient organisations, and centres of excellence in Hong Kong, Japan, Korea, and Taiwan participated in the workshop. Findings Priority areas for action were described along the four axes of the WHO Framework: (1) awareness, advocacy and resources; (2) evidence and data; (3) prevention of transmission; and (4) screening and treatment. Priorities included: axis 1: greater public and professional awareness, particularly among primary care physicians and local advocacy networks. Axis 2: better economic data and identifying barriers to screening and treatment uptake. Axis 3: monitoring of vaccination outcomes and targeted harm reduction strategies. Axis 4: strengthening links between hospitals and primary care providers, and secure funding of screening and treatment, including for hepatocellular carcinoma. Conclusions The WHO Framework provides an opportunity to develop comprehensive and cohesive policies in North Asia and the broader region. A partnership between clinical specialists, primary care physicians, policy makers, and people with or at risk of viral hepatitis is essential in shaping future policies.
doi_str_mv 10.1016/j.jhep.2013.06.029
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1443999752</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827813004479</els_id><sourcerecordid>1443999752</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-3c66345cc560ae15f43adc15c5e16cc9eb2475d983e13c6650cbcb1a51facf4b3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EokPhBVggL9kk2LGdHwkhVRXtIFUU8bu0nJubjtMkDnbSala8eh2mdMGikiV78Z1j3e8S8pqzlDOev-vSbodTmjEuUpanLKuekA3PGUtYLvlTsolQmZRZUR6RFyF0jDHBKvmcHGWiVPGVbcifrzg5P9PWu4Ea-tN609MtTma2sw30i-st7OmZ88tA3UjtMPU44Djb8YrOO6S_tpcxawa8df6ats7Tq97VscPAbGMgnpu_nbuHTjvSz_HLHT0J1rwkz1rTB3x1fx-TH2cfv59uk4vL80-nJxcJyKKYEwF5LqQCUDkzyFUrhWmAK1DIc4AK60wWqqlKgXxlFYMaam4Ubw20shbH5O2hd_Lu94Jh1oMNgH1vRnRL0FxKUVVVobKIZgcUvAvBY6snbwfj95ozvYrXnV7F61W8ZrmO4mPozX3_Ug_YPET-mY7A-wOAccobi14HsDgCNtYjzLpx9vH-D__FobejBdNf4x5D5xY_Rn-a65Bppr-tq183zwVjUhaVuAPku6q_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1443999752</pqid></control><display><type>article</type><title>Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Chen, Ding-Shinn ; Locarnini, Stephen ; Wait, Suzanne ; Bae, Si-Hyun ; Chen, Pei-Jer ; Fung, James Y.Y ; Kim, Hong Soo ; Lu, Sheng-Nan ; Sung, Joseph ; Tanaka, Junko ; Wakita, Takaji ; Ward, John ; Wallace, Jack</creator><creatorcontrib>Chen, Ding-Shinn ; Locarnini, Stephen ; Wait, Suzanne ; Bae, Si-Hyun ; Chen, Pei-Jer ; Fung, James Y.Y ; Kim, Hong Soo ; Lu, Sheng-Nan ; Sung, Joseph ; Tanaka, Junko ; Wakita, Takaji ; Ward, John ; Wallace, Jack ; CEVHAP North Asia Workshop on Viral Hepatitis</creatorcontrib><description>Background &amp; Aims The World Health Organisation (WHO) Prevention &amp; Control of Viral Hepatitis Infection: Framework for Global Action offers a global vision for the prevention and control of viral hepatitis. In October 2012, the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) organised the North Asia Workshop on Viral Hepatitis in Taipei to discuss how to implement the WHO Framework in the North Asia region. This paper presents outcomes from this workshop. Methods Twenty-eight representatives from local liver associations, patient organisations, and centres of excellence in Hong Kong, Japan, Korea, and Taiwan participated in the workshop. Findings Priority areas for action were described along the four axes of the WHO Framework: (1) awareness, advocacy and resources; (2) evidence and data; (3) prevention of transmission; and (4) screening and treatment. Priorities included: axis 1: greater public and professional awareness, particularly among primary care physicians and local advocacy networks. Axis 2: better economic data and identifying barriers to screening and treatment uptake. Axis 3: monitoring of vaccination outcomes and targeted harm reduction strategies. Axis 4: strengthening links between hospitals and primary care providers, and secure funding of screening and treatment, including for hepatocellular carcinoma. Conclusions The WHO Framework provides an opportunity to develop comprehensive and cohesive policies in North Asia and the broader region. A partnership between clinical specialists, primary care physicians, policy makers, and people with or at risk of viral hepatitis is essential in shaping future policies.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2013.06.029</identifier><identifier>PMID: 23850942</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antiviral Agents - therapeutic use ; Asia ; Asia, Northern - epidemiology ; Gastroenterology and Hepatology ; Hepatitis B ; Hepatitis C ; Hepatitis, Viral, Human - drug therapy ; Hepatitis, Viral, Human - epidemiology ; Hepatitis, Viral, Human - prevention &amp; control ; Humans ; Policy ; Policy Making ; Risk Factors ; Viral Vaccines - therapeutic use ; World Health Organization</subject><ispartof>Journal of hepatology, 2013-11, Vol.59 (5), p.1073-1080</ispartof><rights>European Association for the Study of the Liver</rights><rights>2013 European Association for the Study of the Liver</rights><rights>Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-3c66345cc560ae15f43adc15c5e16cc9eb2475d983e13c6650cbcb1a51facf4b3</citedby><cites>FETCH-LOGICAL-c477t-3c66345cc560ae15f43adc15c5e16cc9eb2475d983e13c6650cbcb1a51facf4b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168827813004479$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23911,23912,25120,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23850942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Ding-Shinn</creatorcontrib><creatorcontrib>Locarnini, Stephen</creatorcontrib><creatorcontrib>Wait, Suzanne</creatorcontrib><creatorcontrib>Bae, Si-Hyun</creatorcontrib><creatorcontrib>Chen, Pei-Jer</creatorcontrib><creatorcontrib>Fung, James Y.Y</creatorcontrib><creatorcontrib>Kim, Hong Soo</creatorcontrib><creatorcontrib>Lu, Sheng-Nan</creatorcontrib><creatorcontrib>Sung, Joseph</creatorcontrib><creatorcontrib>Tanaka, Junko</creatorcontrib><creatorcontrib>Wakita, Takaji</creatorcontrib><creatorcontrib>Ward, John</creatorcontrib><creatorcontrib>Wallace, Jack</creatorcontrib><creatorcontrib>CEVHAP North Asia Workshop on Viral Hepatitis</creatorcontrib><title>Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Background &amp; Aims The World Health Organisation (WHO) Prevention &amp; Control of Viral Hepatitis Infection: Framework for Global Action offers a global vision for the prevention and control of viral hepatitis. In October 2012, the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) organised the North Asia Workshop on Viral Hepatitis in Taipei to discuss how to implement the WHO Framework in the North Asia region. This paper presents outcomes from this workshop. Methods Twenty-eight representatives from local liver associations, patient organisations, and centres of excellence in Hong Kong, Japan, Korea, and Taiwan participated in the workshop. Findings Priority areas for action were described along the four axes of the WHO Framework: (1) awareness, advocacy and resources; (2) evidence and data; (3) prevention of transmission; and (4) screening and treatment. Priorities included: axis 1: greater public and professional awareness, particularly among primary care physicians and local advocacy networks. Axis 2: better economic data and identifying barriers to screening and treatment uptake. Axis 3: monitoring of vaccination outcomes and targeted harm reduction strategies. Axis 4: strengthening links between hospitals and primary care providers, and secure funding of screening and treatment, including for hepatocellular carcinoma. Conclusions The WHO Framework provides an opportunity to develop comprehensive and cohesive policies in North Asia and the broader region. A partnership between clinical specialists, primary care physicians, policy makers, and people with or at risk of viral hepatitis is essential in shaping future policies.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Asia</subject><subject>Asia, Northern - epidemiology</subject><subject>Gastroenterology and Hepatology</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Hepatitis, Viral, Human - drug therapy</subject><subject>Hepatitis, Viral, Human - epidemiology</subject><subject>Hepatitis, Viral, Human - prevention &amp; control</subject><subject>Humans</subject><subject>Policy</subject><subject>Policy Making</subject><subject>Risk Factors</subject><subject>Viral Vaccines - therapeutic use</subject><subject>World Health Organization</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhS0EokPhBVggL9kk2LGdHwkhVRXtIFUU8bu0nJubjtMkDnbSala8eh2mdMGikiV78Z1j3e8S8pqzlDOev-vSbodTmjEuUpanLKuekA3PGUtYLvlTsolQmZRZUR6RFyF0jDHBKvmcHGWiVPGVbcifrzg5P9PWu4Ea-tN609MtTma2sw30i-st7OmZ88tA3UjtMPU44Djb8YrOO6S_tpcxawa8df6ats7Tq97VscPAbGMgnpu_nbuHTjvSz_HLHT0J1rwkz1rTB3x1fx-TH2cfv59uk4vL80-nJxcJyKKYEwF5LqQCUDkzyFUrhWmAK1DIc4AK60wWqqlKgXxlFYMaam4Ubw20shbH5O2hd_Lu94Jh1oMNgH1vRnRL0FxKUVVVobKIZgcUvAvBY6snbwfj95ozvYrXnV7F61W8ZrmO4mPozX3_Ug_YPET-mY7A-wOAccobi14HsDgCNtYjzLpx9vH-D__FobejBdNf4x5D5xY_Rn-a65Bppr-tq183zwVjUhaVuAPku6q_</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Chen, Ding-Shinn</creator><creator>Locarnini, Stephen</creator><creator>Wait, Suzanne</creator><creator>Bae, Si-Hyun</creator><creator>Chen, Pei-Jer</creator><creator>Fung, James Y.Y</creator><creator>Kim, Hong Soo</creator><creator>Lu, Sheng-Nan</creator><creator>Sung, Joseph</creator><creator>Tanaka, Junko</creator><creator>Wakita, Takaji</creator><creator>Ward, John</creator><creator>Wallace, Jack</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20131101</creationdate><title>Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia</title><author>Chen, Ding-Shinn ; Locarnini, Stephen ; Wait, Suzanne ; Bae, Si-Hyun ; Chen, Pei-Jer ; Fung, James Y.Y ; Kim, Hong Soo ; Lu, Sheng-Nan ; Sung, Joseph ; Tanaka, Junko ; Wakita, Takaji ; Ward, John ; Wallace, Jack</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-3c66345cc560ae15f43adc15c5e16cc9eb2475d983e13c6650cbcb1a51facf4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Asia</topic><topic>Asia, Northern - epidemiology</topic><topic>Gastroenterology and Hepatology</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Hepatitis, Viral, Human - drug therapy</topic><topic>Hepatitis, Viral, Human - epidemiology</topic><topic>Hepatitis, Viral, Human - prevention &amp; control</topic><topic>Humans</topic><topic>Policy</topic><topic>Policy Making</topic><topic>Risk Factors</topic><topic>Viral Vaccines - therapeutic use</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Ding-Shinn</creatorcontrib><creatorcontrib>Locarnini, Stephen</creatorcontrib><creatorcontrib>Wait, Suzanne</creatorcontrib><creatorcontrib>Bae, Si-Hyun</creatorcontrib><creatorcontrib>Chen, Pei-Jer</creatorcontrib><creatorcontrib>Fung, James Y.Y</creatorcontrib><creatorcontrib>Kim, Hong Soo</creatorcontrib><creatorcontrib>Lu, Sheng-Nan</creatorcontrib><creatorcontrib>Sung, Joseph</creatorcontrib><creatorcontrib>Tanaka, Junko</creatorcontrib><creatorcontrib>Wakita, Takaji</creatorcontrib><creatorcontrib>Ward, John</creatorcontrib><creatorcontrib>Wallace, Jack</creatorcontrib><creatorcontrib>CEVHAP North Asia Workshop on Viral Hepatitis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Ding-Shinn</au><au>Locarnini, Stephen</au><au>Wait, Suzanne</au><au>Bae, Si-Hyun</au><au>Chen, Pei-Jer</au><au>Fung, James Y.Y</au><au>Kim, Hong Soo</au><au>Lu, Sheng-Nan</au><au>Sung, Joseph</au><au>Tanaka, Junko</au><au>Wakita, Takaji</au><au>Ward, John</au><au>Wallace, Jack</au><aucorp>CEVHAP North Asia Workshop on Viral Hepatitis</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>59</volume><issue>5</issue><spage>1073</spage><epage>1080</epage><pages>1073-1080</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><abstract>Background &amp; Aims The World Health Organisation (WHO) Prevention &amp; Control of Viral Hepatitis Infection: Framework for Global Action offers a global vision for the prevention and control of viral hepatitis. In October 2012, the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) organised the North Asia Workshop on Viral Hepatitis in Taipei to discuss how to implement the WHO Framework in the North Asia region. This paper presents outcomes from this workshop. Methods Twenty-eight representatives from local liver associations, patient organisations, and centres of excellence in Hong Kong, Japan, Korea, and Taiwan participated in the workshop. Findings Priority areas for action were described along the four axes of the WHO Framework: (1) awareness, advocacy and resources; (2) evidence and data; (3) prevention of transmission; and (4) screening and treatment. Priorities included: axis 1: greater public and professional awareness, particularly among primary care physicians and local advocacy networks. Axis 2: better economic data and identifying barriers to screening and treatment uptake. Axis 3: monitoring of vaccination outcomes and targeted harm reduction strategies. Axis 4: strengthening links between hospitals and primary care providers, and secure funding of screening and treatment, including for hepatocellular carcinoma. Conclusions The WHO Framework provides an opportunity to develop comprehensive and cohesive policies in North Asia and the broader region. A partnership between clinical specialists, primary care physicians, policy makers, and people with or at risk of viral hepatitis is essential in shaping future policies.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23850942</pmid><doi>10.1016/j.jhep.2013.06.029</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-8278
ispartof Journal of hepatology, 2013-11, Vol.59 (5), p.1073-1080
issn 0168-8278
1600-0641
language eng
recordid cdi_proquest_miscellaneous_1443999752
source MEDLINE; Elsevier ScienceDirect Journals
subjects Antiviral Agents - therapeutic use
Asia
Asia, Northern - epidemiology
Gastroenterology and Hepatology
Hepatitis B
Hepatitis C
Hepatitis, Viral, Human - drug therapy
Hepatitis, Viral, Human - epidemiology
Hepatitis, Viral, Human - prevention & control
Humans
Policy
Policy Making
Risk Factors
Viral Vaccines - therapeutic use
World Health Organization
title Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T03%3A03%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Report%20from%20a%20Viral%20Hepatitis%20Policy%20Forum%20on%20implementing%20the%20WHO%20framework%20for%20global%20action%20on%20viral%20hepatitis%20in%20North%20Asia&rft.jtitle=Journal%20of%20hepatology&rft.au=Chen,%20Ding-Shinn&rft.aucorp=CEVHAP%20North%20Asia%20Workshop%20on%20Viral%20Hepatitis&rft.date=2013-11-01&rft.volume=59&rft.issue=5&rft.spage=1073&rft.epage=1080&rft.pages=1073-1080&rft.issn=0168-8278&rft.eissn=1600-0641&rft_id=info:doi/10.1016/j.jhep.2013.06.029&rft_dat=%3Cproquest_cross%3E1443999752%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1443999752&rft_id=info:pmid/23850942&rft_els_id=S0168827813004479&rfr_iscdi=true